Rayos

(Prednisone)

ApprovedSmall molecule

Prednisone is a steroid medication that reduces inflammation and suppresses the immune system, used to treat conditions like allergies, asthma, arthritis, and certain autoimmune diseases.[2] Rayos is currently approved and in use across 226 indications[4].[1]

Rayos is one of 1952 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Approved.

226

Indications

1,237

Total Trials

Active Trials

1,951

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Prostate AdenocarcinomaRecruiting

T-Cell Acute Lymphoblastic LeukemiaCompleted

EfficacyCompleted

Cardiac SarcoidosisActive, not recruiting

Vestibular NeuronitisActive, not recruiting

AsthmaUnknown status

Efficacy and SafetyRecruiting

Abiraterone AcetateRecruiting

LymphomaUnknown status

Prostate AdenocarcinomaApproved

Recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Completed

EfficacyPhase 3

Completed

Cardiac SarcoidosisApproved

Active, not recruiting

Vestibular NeuronitisApproved

Active, not recruiting

Recruiting

AsthmaApproved

Unknown status

Efficacy and SafetyApproved

Recruiting

Abiraterone AcetatePhase 3

Recruiting

LymphomaPhase 3

Unknown status

Showing 10 of 225 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Rayos

Zofran

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Pregnancy

NCT04918524

Q1 2027

Phase 2Active, not recruiting

Prostate Cancer

NCT03012321

Q2 2027

Post-ApprovalRecruiting

Steroid

NCT03153527

Recruiting

Real-World Study

NCT05899621

Q3 2027

Post-ApprovalRecruiting

Interstitial Nephritis

NCT04376216

Clinical

Trials by Indication[1]

Lymphoma31 trials

Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00039351·32 enrolled

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001337·348 enrolled

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Completed·UUniversität des Saarlandes·Phase 2·NCT00726700·109 enrolled

Show 28 more trials

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

Unknown status·—·Phase 1/2·NCT00363090·84 enrolled

Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002618·242 enrolled

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT02809573·30 enrolled

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028717·400 enrolled

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00070018·46 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Completed·SSwiss Cancer Institute·Phase 3·NCT00003215·400 enrolled

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00005089·71 enrolled

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT01569204·100 enrolled

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT01775475·7 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005959

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05008224·146 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 3·NCT00004112

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Completed·UUniversity of Chicago·Phase 1/2·NCT02213913·55 enrolled

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Withdrawn·—·N/A·NCT00110006

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004179·475 enrolled

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Completed·EEmory University·Phase 1/2·NCT00634179·37 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003150·630 enrolled

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Completed·UUNICANCER·Phase 3·NCT00003650·179 enrolled

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00045500

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00005584·1,649 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00389818·43 enrolled

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193479·51 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00107380·86 enrolled

Prostate Cancer24 trials

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Completed·UUniversity of Washington·Phase 2·NCT01503229·32 enrolled

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Withdrawn·—·Phase 2·NCT01750866

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT04666129·48 enrolled

Show 21 more trials

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

Terminated·UUniversity of Utah·Phase 2·NCT03827473·1 enrolled

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00004071

Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04356430·75 enrolled

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Completed· Astellas logo

Astellas·Phase 1/2·NCT00514267·32 enrolled

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02924766·34 enrolled

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00087165·22 enrolled

OGX-427 in Castration Resistant Prostate Cancer Patients

Completed·BBritish Columbia Cancer Agency·Phase 2·NCT01120470·74 enrolled

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Withdrawn·NNew Mexico Cancer Research Alliance·Phase 2·NCT01478308

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Unknown status·CConsorzio Oncotech·Phase 2·NCT03356912·220 enrolled

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Terminated·EExelixis·Phase 3·NCT01522443·119 enrolled

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00137436·93 enrolled

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

Completed·UUniversity of Washington·Phase 2·NCT01023061·24 enrolled

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·SSWOG Cancer Research Network·Phase 3·NCT00004001·770 enrolled

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Completed· Takeda logo

Takeda·Phase 1/2·NCT01666314·137 enrolled

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting·NNorthwestern University·Phase 2·NCT03012321·70 enrolled

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Withdrawn·BBaptist Health South Florida·Phase 1/2·NCT06329830

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01145508·10 enrolled

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·MMacroGenics·Phase 2·NCT05848011·154 enrolled

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Terminated·CCostantine Albany·Phase 2·NCT01681433·72 enrolled

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02217566·46 enrolled

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Completed·—·Phase 2·NCT01637402·41 enrolled

Acute Lymphoblastic Leukemia10 trials

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01156883·76 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Show 7 more trials

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00458848·470 enrolled

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00018954

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT02523976·30 enrolled

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05660473·100 enrolled

Multiple Myeloma6 trials

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002678·595 enrolled

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01335685·61 enrolled

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Show 3 more trials

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02474563·171 enrolled

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT00551928·402 enrolled

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002653·1,000 enrolled

Rheumatoid Arthritis5 trials

Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.

Completed·PP. Verschueren·Phase 4·NCT01172639·400 enrolled

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 2·NCT01393639·323 enrolled

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Completed·ZZalicus·Phase 2·NCT01369745·294 enrolled

Show 2 more trials

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00634933·222 enrolled

Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis

Terminated·ZZalicus·Phase 2·NCT01612377·18 enrolled

88 more indications

Follicular Lymphoma4 trials

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Withdrawn·SSecuraBio·Phase 2·NCT02605694

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05371093·231 enrolled

Show 1 more trial

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled

Mantle Cell Lymphoma4 trials

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00070447

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003541·24 enrolled

Show 1 more trial

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00376961·68 enrolled

Chronic Graft Versus Host Disease4 trials

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

Completed·SStanford University·Phase 2·NCT00388362·36 enrolled

Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity

Recruiting·BByung-Sik Cho·Phase 2·NCT06756061·88 enrolled

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00031824·82 enrolled

Show 1 more trial

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Completed·PPharmacyclics LLC.·Phase 3·NCT02959944·193 enrolled

Acute Graft Versus Host Disease4 trials

A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04220632·1 enrolled

Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00929695·164 enrolled

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Completed· Incyte logo

Incyte·Phase 3·NCT03139604·439 enrolled

Show 1 more trial

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00357084·53 enrolled

Steroid3 trials

Taper Or Abrupt Steroid Stop: TOASSTtrial

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT03153527·530 enrolled

Pre-operative Steroids in CRSsP

Withdrawn·LLoma Linda University·Phase 2/3·NCT05095961

Comparison Between Corticosteroid and Topical Steroids in the DRESS

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01987076·112 enrolled

Diffuse Large B-Cell Lymphoma3 trials

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03274492·1,000 enrolled

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed·BBritish Columbia Cancer Agency·Phase 1·NCT00070083

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated· Roche logo

Roche·Phase 1·NCT04790903·50 enrolled

Pneumonia3 trials

Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial

Completed·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT00973154·800 enrolled

Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia

Terminated·UUniversity of Chile·Phase 3·NCT04451174·60 enrolled

Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT04534478·120 enrolled

Kidney Transplant3 trials

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

Completed·MMedical University of South Carolina·N/A·NCT02954198·40 enrolled

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Completed·AAssociação Médico Espírita de Botucatu·Phase 4·NCT02683291·48 enrolled

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Completed·MMayo Clinic·Phase 4·NCT00275535·165 enrolled

Myocarditis2 trials

Myocarditis Treatment Trial

Completed·UUniversity of Utah·Phase 2·NCT00000524

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·Phase 2·NCT00004482·40 enrolled

Giant Cell Arteritis2 trials

Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis

Completed·TThe Cleveland Clinic·Phase 2·NCT00004686·300 enrolled

Ustekinumab for the Treatment of Giant Cell Arteritis

Terminated·MMassachusetts General Hospital·Phase 1/2·NCT02955147·13 enrolled

Safety and Efficacy2 trials

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03283202·35 enrolled

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00541281·150 enrolled

Chronic Rhinosinusitis2 trials

Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.

Completed·—·Phase 3·NCT03687515·91 enrolled

The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis

Completed·KKafrelsheikh University·Phase 2/3·NCT05931744·120 enrolled

Bullous Pemphigoid2 trials

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Completed· Argenx logo

Argenx·Phase 2/3·NCT05267600·98 enrolled

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

Completed·UUniversity of Iowa·Phase 4·NCT00472030·2 enrolled

Hodgkin's Disease2 trials

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002462·615 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease

Completed·SStanford University·Phase 2·NCT00002714

Metastatic Prostate Cancer2 trials

Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00003343·525 enrolled

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·GGroupe D'Etude des Tumeurs Uro-Genitales·Phase 2·NCT00627354·90 enrolled

Multiple Sclerosis2 trials

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00014755·35 enrolled

Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis

Terminated·CClaudio Gobbi·Phase 4·NCT01411514·27 enrolled

Treatment2 trials

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

Completed·MMedical College of Wisconsin·Phase 2·NCT02806947·127 enrolled

Pulmonary Sarcoidosis2 trials

Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05247554·200 enrolled

Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).

Completed·UUniversity of Milano Bicocca·Phase 3·NCT02200146·94 enrolled

Leukemia2 trials

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Unknown status·GGrupo Argentino de Tratamiento de la Leucemia Aguda·Phase 2/3·NCT00002499

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01000285·18 enrolled

Fibrosis2 trials

Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis

Unknown status·UUniversity of Parma·Phase 2·NCT00440349·38 enrolled

Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial

Unknown status·UUniversity of Parma·Phase 3·NCT01240850·200 enrolled

Stem Cell Transplantation2 trials

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004232

Efficacy2 trials

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

Completed·MMereo BioPharma·Phase 2·NCT01332097·183 enrolled

Asthma2 trials

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Completed·NNorthwell Health·Phase 3·NCT00588406·95 enrolled

Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma

Completed·—·Phase 4·NCT01241006·376 enrolled

Thrombocytopenic Purpura2 trials

Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone

Completed·IIsfahan University of Medical Sciences·Phase 2/3·NCT02914054·36 enrolled

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Completed·MMayo Clinic·Phase 1·NCT00486421·22 enrolled

Adult1 trial

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT02767089·37 enrolled

Trial1 trial

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Terminated·VVeeda Oncology·Phase 2·NCT00313482·35 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.

Unknown status·RRabin Medical Center·Phase 4·NCT02237820·80 enrolled

Lupus Nephritis1 trial

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Completed· Roche logo

Roche·Phase 2·NCT02550652·126 enrolled

Phase 11 trial

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

Recruiting·DDualityBio Inc.·Phase 1/2·NCT06625671·148 enrolled

Idiopathic Nephrotic Syndrome1 trial

Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome

Unknown status·RRadboud University Medical Center·Phase 3·NCT03298698·40 enrolled

Cancer of the Prostate1 trial

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

Withdrawn·JJohn P. Fruehauf·Phase 2·NCT00598858

Fatigue1 trial

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

Completed·AAmpel BioSolutions, LLC·Phase 4·NCT03098823·62 enrolled

Pregnancy1 trial

The Clinical Features and Pregnancy Outcomes of CTD Patients

Recruiting·QQilu Hospital of Shandong University··NCT04918524·126 enrolled

Abiraterone Acetate1 trial

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Completed·AAstex Pharmaceuticals, Inc.·Phase 1/2·NCT01685268·49 enrolled

Double-blind1 trial

TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Completed·OOttawa Hospital Research Institute·Phase 2/3·NCT00789997·81 enrolled

DMD1 trial

CoQ10 and Prednisone in Non-Ambulatory DMD

Terminated·CCooperative International Neuromuscular Research Group·Phase 3·NCT00308113·3 enrolled

mCRPC1 trial

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Completed·RRahul Aggarwal·Phase 1/2·NCT02494921·43 enrolled

Immunosuppressive Treatment1 trial

Different Immunosuppressive Treatment in iMN

Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT04745728·200 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Myelofibrosis1 trial

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Completed·MMayo Clinic·Phase 2·NCT00445900·22 enrolled

Monoclonal1 trial

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

Completed· Astellas logo

Astellas·Phase 2·NCT00693524·94 enrolled

Polymyalgia Rheumatica1 trial

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Terminated· Novartis logo

Novartis·Phase 2·NCT01364389·16 enrolled

Advanced Stage1 trial

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Monotherapy1 trial

Ozurdex Monotherapy Trial

Withdrawn·OOttawa Hospital Research Institute·Phase 4·NCT05101928

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Telitacicept1 trial

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Chronic Kidney Disease1 trial

Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

Suspended·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04844814·204 enrolled

Thrombotic Thrombocytopenic Purpura1 trial

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Completed·OOhio State University·Phase 3·NCT00713193·26 enrolled

Hypereosinophilic syndrome1 trial

Steroid Treatment for Hypereosinophilic Syndrome

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01524536·26 enrolled

Vasculitis1 trial

The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children

Unknown status·—·Phase 3·NCT03692416·70 enrolled

Hemangioma1 trial

Randomized Study of Hormonal Regulation of Infantile Hemangioma

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004436·30 enrolled

Lymphoid Malignancies1 trial

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT05371054·8 enrolled

Hepatitis1 trial

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

Completed·IIndiana University·Phase 2·NCT04072822·147 enrolled

Hypersensitivity1 trial

Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers

Completed·IInnovaderm Research Inc.·N/A·NCT03625219·54 enrolled

Inflammatory Bowel Disease1 trial

Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease

Completed·UUniversity of British Columbia·Phase 4·NCT01981889·53 enrolled

Liquid Biopsy1 trial

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Unknown status·FFudan University··NCT05188911·30 enrolled

Absorption1 trial

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06566989·8 enrolled

Hematologic Malignancies1 trial

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Completed·—·Phase 1·NCT01888952·10 enrolled

Chronic Lymphocytic Leukemia1 trial

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Completed·GGerman CLL Study Group·Phase 2·NCT00309881·75 enrolled

Renal Transplant1 trial

Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 4·NCT00419926·313 enrolled

Ulcerative Colitis1 trial

Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis

Terminated·GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa·Phase 4·NCT02921555·75 enrolled

Cardiovascular1 trial

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Withdrawn·UUniversity of Saskatchewan·Phase 4·NCT02058875

Sudden Sensorineural Hearing Loss1 trial

High Dose Oral Steroids in Sudden Sensorineural Hearing Loss

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT03255473

T-cell non-Hodgkin lymphoma1 trial

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

Withdrawn·UUniversity of Miami·N/A·NCT00513188

Corticosteroids1 trial

A Study of the Effects of Single Dose Corticosteroids on Response to Allergens

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00828061·19 enrolled

Prostate Carcinoma1 trial

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Completed·VVA Office of Research and Development·Phase 3·NCT00132301·298 enrolled

Renal Transplant Recipients1 trial

Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT00413920·222 enrolled

Graft Versus Host Disease1 trial

Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00043147

Pruritus1 trial

Aprepitant in the Management of Biological Therapies-related Severe Pruritus

Completed·—·Phase 2·NCT01683552·45 enrolled

Cellulitis1 trial

The Use of Oral Steroids in the Treatment of Cellulitis

Withdrawn·MMilton S. Hershey Medical Center·Phase 2·NCT00893048

Single Dose1 trial

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

Completed· Pfizer logo

Pfizer·Phase 1·NCT01199029·18 enrolled

Newly Diagnosed1 trial

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05887726·30 enrolled

Glucocorticoid1 trial

Short Course Glucocorticoid Treatment for PTSD

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT00204737·12 enrolled

Croup1 trial

Community Care for Croup (RCT)

Completed·WWashington University School of Medicine·Phase 4·NCT01042145·87 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00853008·100 enrolled

Unknown status·LLymphoma Trials Office·Phase 3·NCT00003578·500 enrolled

Uveitis1 trial

Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01124838·261 enrolled

Restless Legs Syndrome1 trial

A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study

Not yet recruiting·SScripps Health·Phase 1/2·NCT06631300·50 enrolled

Kidney Cancer1 trial

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Completed·UUniversity of New Mexico·Phase 2·NCT00003584·35 enrolled

Deafness1 trial

Sudden Deafness Treatment Trial

Completed·MMassachusetts Eye and Ear Infirmary·Phase 3·NCT00097448·255 enrolled

Duchenne Muscular Dystrophy1 trial

High-dose Prednisone in Duchenne Muscular Dystrophy

Completed·CCooperative International Neuromuscular Research Group·Phase 3·NCT00110669·64 enrolled

Optic Neuritis1 trial

Longitudinal Optic Neuritis Study (LONS)

Unknown status·NNational Eye Institute (NEI)·N/A·NCT00000147

Respiratory tract infection1 trial

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Terminated·MMaisonneuve-Rosemont Hospital·Phase 2·NCT01432080·12 enrolled

Liver Transplant1 trial

Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00149994·171 enrolled

Interstitial Nephritis1 trial

Prednisolone Treatment in Acute Interstitial Nephritis

Recruiting·RRegion MidtJylland Denmark·Phase 4·NCT04376216·110 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DELTASONE

NDA NDA009986

Jan 1, 1982

METICORTEN

NDA NDA009766

Jan 1, 1982

PARACORT

NDA NDA010962

Jan 1, 1982

PREDNISONE

NDA NDA017109

Jul 26, 2012

RAYOS

NDA NDA202020

Sources

References

[1]
ClinicalTrials.gov — 1237 trial records for Prednisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Rayos drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Prednisone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Prednisone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202020). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Rayos. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Roxane Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: RRoxane Laboratories

Patent Landscape[6]

Patent Cliff

Aug 3, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9504699Aug 3, 2027

8168218Jan 7, 2028